[go: up one dir, main page]

CL2017001930A1 - Derivados de 4h-pirrol[3,2-c]piridin-4-ona - Google Patents

Derivados de 4h-pirrol[3,2-c]piridin-4-ona

Info

Publication number
CL2017001930A1
CL2017001930A1 CL2017001930A CL2017001930A CL2017001930A1 CL 2017001930 A1 CL2017001930 A1 CL 2017001930A1 CL 2017001930 A CL2017001930 A CL 2017001930A CL 2017001930 A CL2017001930 A CL 2017001930A CL 2017001930 A1 CL2017001930 A1 CL 2017001930A1
Authority
CL
Chile
Prior art keywords
pyridin
pyrrole
derivatives
drugs
processes
Prior art date
Application number
CL2017001930A
Other languages
English (en)
Inventor
Philip Lienau
Gerhard Siemeister
Hans Briem
Volker Schulze
Ulrich Klar
Keith Graham
René Tempel
Jozsef Bálint
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2017001930A1 publication Critical patent/CL2017001930A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>COMPUESTOS DE FÓRMULA (I), PROCESOS PARA SU PRODUCCIÓN Y SU USO COMO FÁRMACOS.</p>
CL2017001930A 2015-01-28 2017-07-28 Derivados de 4h-pirrol[3,2-c]piridin-4-ona CL2017001930A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15152944 2015-01-28
EP15200407 2015-12-16

Publications (1)

Publication Number Publication Date
CL2017001930A1 true CL2017001930A1 (es) 2018-03-09

Family

ID=55236350

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001930A CL2017001930A1 (es) 2015-01-28 2017-07-28 Derivados de 4h-pirrol[3,2-c]piridin-4-ona

Country Status (30)

Country Link
US (1) US10428063B2 (es)
EP (1) EP3250567B1 (es)
JP (1) JP6704398B2 (es)
KR (1) KR102544847B1 (es)
CN (1) CN107406417B (es)
AU (1) AU2016212230B2 (es)
BR (1) BR112017016193B1 (es)
CA (1) CA2974853C (es)
CL (1) CL2017001930A1 (es)
CO (1) CO2017007663A2 (es)
CR (1) CR20170345A (es)
CU (1) CU20170094A7 (es)
DO (1) DOP2017000176A (es)
EA (1) EA032530B1 (es)
EC (1) ECSP17048527A (es)
IL (1) IL253284B (es)
JO (1) JO3706B1 (es)
MX (1) MX380239B (es)
MY (1) MY182181A (es)
NI (1) NI201700096A (es)
PE (1) PE20171240A1 (es)
PH (1) PH12017501340A1 (es)
SG (1) SG11201705908VA (es)
SV (1) SV2017005487A (es)
TN (1) TN2017000329A1 (es)
TW (1) TWI699359B (es)
UA (1) UA122221C2 (es)
UY (1) UY36544A (es)
WO (1) WO2016120196A1 (es)
ZA (1) ZA201705802B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708211T3 (es) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CA2994596A1 (en) * 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
CR20180367A (es) 2015-12-16 2018-11-12 Loxo Oncology Inc [ Compuestos útiles como inhibidores de cinasa
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102440006B1 (ko) 2017-08-23 2022-09-05 현대모비스 주식회사 차량용 브레이크의 캘리퍼 장치
CA3079786A1 (en) 2017-10-24 2019-05-02 The Broad Institute, Inc. 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
US12403135B2 (en) * 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
EP3959211A1 (en) * 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
US20230339939A1 (en) 2020-07-29 2023-10-26 Bayer Aktiengesellschaft Substituted 1h-pyrrolo[3,2-b]pyridine compounds and methods of use thereof
WO2022023337A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
TW202220987A (zh) 2020-07-29 2022-06-01 德商拜耳廠股份有限公司 經取代雜環化合物及其治療用途
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
EP4217070A1 (en) 2020-09-23 2023-08-02 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
CN116997549A (zh) * 2020-09-23 2023-11-03 蝎子疗法股份有限公司 用于治疗癌症的吡咯并[3,2-c]吡啶-4-酮衍生物
WO2022072645A2 (en) * 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
KR20230107419A (ko) * 2020-10-09 2023-07-14 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료 방법
CN116981667A (zh) * 2020-10-09 2023-10-31 蝎子疗法股份有限公司 用于癌症治疗的egfr和/或her2的杂环抑制剂
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
US20250188075A1 (en) * 2022-01-27 2025-06-12 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
US20250197391A1 (en) 2022-03-24 2025-06-19 Scorpion Therapeutics, Inc. Methods of synthesizing egfr inhibitors
WO2024182715A1 (en) * 2023-03-02 2024-09-06 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US8426417B2 (en) 2007-09-28 2013-04-23 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
WO2009093012A1 (en) * 2008-01-22 2009-07-30 Vernalis (R & D) Ltd Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
WO2013050448A1 (en) * 2011-10-07 2013-04-11 Nerviano Medical Sciences S.R.L. 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
JP5771750B2 (ja) 2011-10-28 2015-09-02 チョン クン ダン ファーマシューティカル コーポレーション Ｈｄａｃ阻害剤用のヒドロキサメート誘導体およびこれを含む薬学的組成物
CN104125957B (zh) 2011-12-21 2016-05-25 拜耳知识产权有限责任公司 取代的苄基吡唑
EP2847180B1 (en) 2012-05-11 2017-01-04 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
CN104870446B (zh) 2012-11-07 2019-08-13 内尔维阿诺医学科学有限公司 取代的嘧啶基和吡啶基吡咯并吡啶酮类、其制备方法及其作为激酶抑制剂的用途
EP2976336A1 (en) * 2013-03-21 2016-01-27 Bayer Pharma Aktiengesellschaft 3-heteroaryl substituted indazoles
CN105164116A (zh) 2013-03-21 2015-12-16 拜耳制药股份公司 杂芳基取代的吲唑
CN105408324A (zh) 2013-06-21 2016-03-16 拜耳制药股份公司 取代的苄基吡唑
EP3010911A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Heteroaryl substituted pyrazoles
HK1223098A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
CN105452236A (zh) 2013-06-21 2016-03-30 拜耳制药股份公司 取代的苄基吡唑
AR097325A1 (es) 2013-08-13 2016-03-09 Gruenenthal Gmbh Pirroles anillados
ES2708211T3 (es) 2014-06-17 2019-04-09 Bayer Pharma AG 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
US10227299B2 (en) 2015-06-17 2019-03-12 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
CA2994596A1 (en) 2015-08-05 2017-02-09 Bayer Pharma Aktiengesellschaft 1h-pyrrol-3-amines
CA3008393A1 (en) 2015-12-16 2017-06-22 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones

Also Published As

Publication number Publication date
UA122221C2 (uk) 2020-10-12
AU2016212230B2 (en) 2019-09-19
CR20170345A (es) 2017-09-29
MY182181A (en) 2021-01-18
ECSP17048527A (es) 2017-10-31
TN2017000329A1 (en) 2019-01-16
CN107406417A (zh) 2017-11-28
NI201700096A (es) 2017-10-24
KR20170106452A (ko) 2017-09-20
HK1244804A1 (zh) 2018-08-17
JP2018503648A (ja) 2018-02-08
BR112017016193A2 (pt) 2018-04-17
ZA201705802B (en) 2019-07-31
EP3250567B1 (en) 2019-10-30
SV2017005487A (es) 2019-01-17
EA201791692A1 (ru) 2018-01-31
CN107406417B (zh) 2020-06-09
US20180016272A1 (en) 2018-01-18
US10428063B2 (en) 2019-10-01
CO2017007663A2 (es) 2017-10-10
SG11201705908VA (en) 2017-08-30
IL253284A0 (en) 2017-09-28
KR102544847B1 (ko) 2023-06-16
JP6704398B2 (ja) 2020-06-03
WO2016120196A1 (en) 2016-08-04
DOP2017000176A (es) 2017-08-31
MX380239B (es) 2025-03-12
AU2016212230A1 (en) 2017-07-20
TW201639828A (zh) 2016-11-16
UY36544A (es) 2016-08-31
EP3250567A1 (en) 2017-12-06
BR112017016193B1 (pt) 2023-02-23
TWI699359B (zh) 2020-07-21
CA2974853A1 (en) 2016-08-04
EA032530B1 (ru) 2019-06-28
IL253284B (en) 2020-08-31
CU20170094A7 (es) 2017-12-08
MX2017009831A (es) 2017-11-02
CA2974853C (en) 2023-02-21
JO3706B1 (ar) 2021-01-31
PH12017501340A1 (en) 2017-12-18
PE20171240A1 (es) 2017-08-24

Similar Documents

Publication Publication Date Title
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EP3572413A4 (en) 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE DERIVATIVE USED AS A WEE1 INHIBITOR
ECSP16000724A (es) Carboxamidas de anillo de 4 miembros empleadas como nematicidas
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX374558B (es) Compuestos de heteroarilo y sus usos.
NI201500119A (es) Compuestos de heteroarilo y sus usos
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
UY35500A (es) Indazoles sustituidos con heteroarilo
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
ECSP20021132A (es) Enantiómeros de tiazoles sustituidos compuestos antivirales
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
CL2016002207A1 (es) Compuestos derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona, con actividad antibacteriana gram (+) y gram (-); composicion farmacéutica que los comprende.
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
UY35665A (es) ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?.
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.